Pharmafile Logo
Pharmafocus logo
Advanced Search

eric low

Showing 7 posts of 7 posts found.

Eric Low

Open access research partnership to ‘crowdsource’ new myeloma drugs

January 27, 2016
Research and Development Myeloma UK, Structural Genomics Consortium, collaboration, eric low, myeloma, partnership

Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership to find new drug targets …

News
Ninlaro

Takeda in myeloma research drive

January 14, 2016
Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma

Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …

News
Eric Low image

Myeloma charity body publishes its first trial results

June 9, 2015
Research and Development, Sales and Marketing ctn, eric low, muk one, myeloma

The Myeloma UK Clinical Trial Network (CTN) has published data from its first trial marking a major milestone for the …

News
Low image

How can ‘innovation’ be defined?

April 14, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, NHS, UK, eric low, innovation, myeloma

Innovation has been and continues to be an important topic of discussion for a number of different stakeholders and disciplines …

Feature
Velcade image

NICE needs more Velcade data

November 12, 2013
Sales and Marketing NHS, NICE, Velcade, eric low

NICE has slowed the progress of Janssen Cilag’s Velcade towards becoming an NHS treatment for multiple myeloma by asking the …

News

The CDF: friend and foe?

November 11, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, Cancer, NICE, eric low

Few things in my professional life have troubled me more than the Cancer Drugs Fund (CDF) since its inception in …

Feature
Eric Low image

Trials and tribulations

October 14, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, eric low, myeloma, transparency

I have been chief executive of Myeloma UK since its inception 17 years ago, and its unique bedside to bench …

Feature

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024